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Abstract
Given the frequency with which MAP kinase signaling is dysregulated in cancer, much effort
has been focused on inhibiting RAS signaling for therapeutic benefit. KSR1, a pseudokinase
that interacts with RAF, is a potential target; it was originally cloned in screens for suppres-
sors of constitutively active RAS, and its deletion prevents RAS-mediated transformation of
mouse embryonic fibroblasts. In this work, we used a genetically engineered mouse model
of pancreatic cancer to assess whether KSR1 deletion would influence tumor development
in the setting of oncogenic RAS. We found that Ksr1-/- mice on this background had a mod-
est but significant improvement in all-cause morbidity compared to Ksr1+/+ and Ksr1+/-
cohorts. Ksr1-/- mice, however, still developed tumors, and precursor pancreatic intraepithe-
lial neoplastic (PanIN) lesions were detected within a similar timeframe compared to Ksr1+/+
mice. No significant differences in pERK expression or in proliferation were noted. RNA
sequencing also did not reveal any unique genetic signature in Ksr1-/- tumors. Further stud-
ies will be needed to determine whether and in what settings KSR inhibition may be clinically
useful.
Introduction
KSR was originally cloned in Drosophila and C. elegans in separate screens for loss of function
mutations that suppressed a constitutively active RAS protein [1–3]. KSR shares high homol-
ogy with the RAF family of kinases, but the mammalian form lacks a catalytic lysine and so it
has been characterized as a pseudokinase. It is proposed to function as a scaffold for RAF,
MEK and ERK [3–9]. There are two isoforms, KSR1 and KSR2; data compiled in the Human
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Protein Atlas indicates that KSR1 mRNA expression is more ubiquitous, while KSR2 is mainly
expressed in the brain [10]. Ksr1-/- mice are phenotypically normal but have modest defects in
T cell activation and long-term associative memory formation [11, 12]. In a mouse model of
breast cancer based on a viral oncogene, the absence of KSR1 results in reduced tumor fre-
quency and progression [11].
Mouse embryonic fibroblasts derived from Ksr1-/- mice exhibit a significant reduction in
EGF- and TPA-induced MAPK activation [13] and importantly, KSR1 is required for RAS-
induced transformation [14, 15]. Furthermore, in a v-Ha-ras mouse model of skin papilloma,
KSR1 deletion attenuates papilloma formation [13]. Lastly, antisense oligonucleotides to KSR1
are able to reduce tumor growth of KRAS-dependent human pancreatic carcinoma xenografts
in nude mice [16].
These data support a role for KSR1 in the context of RAS-driven tumor growth, but KSR1
deficiency has not yet been tested in a genetically engineered mouse model of constitutively
active RAS. One well-studied mouse model of RAS-driven pancreatic cancer combines a con-
ditional oncogenic KRAS allele induced by a pancreatic-specific Cre on the background of a
loss of either the tumor suppressor p53 or INK4/ARF, (reviewed in [17, 18]). This model reca-
pitulates the progression of histological lesions that characterize human pancreatic ductal ade-
nocarcinoma [19]. In this work, we sought to establish whether KSR1 deletion could influence




Mouse strains used in this study were: Ksr1-/- [11], Pdx1-Cre [19], p53flox/flox [20], LSL-
KrasG12D/+ [21]. Mice were maintained on a C57BL/6 background. All mouse experiments
were conducted with prior approval of the Washington University Animal Care and Use Com-
mittee. Animals were kept in conventional animal facilities and monitored daily by trained
husbandry staff. Weights were charted weekly. Criteria for a humane endpoint were chosen to
minimize animal suffering and included any weight loss or gain outside expected physiologic
changes, changes in physical appearance that could cause distress including the development
of rectal prolapse or other anatomic abnormalities, and changes in behavior including signs of
lethargy. When required, mice were euthanized with CO2 according to Institutional Animal
Care and Use Committee (IACUC) guidelines. Consistent with our intent to maintain a
humane endpoint, tumor burden in sacrificed mice was always found to be less than 20mm.
Although rare, mice that died before showing any signs of morbidity were analyzed with nec-
ropsy when possible. In these cases, tumor burden was never found to be more than 20mm.
Histology
Immediately after animal sacrifice, the whole pancreas plus any visible tumor was removed for
histological analysis. To study the phenomenon of rectal prolapse, the gastrointestinal tract
was removed from the duodenum to the rectum. Immunohistochemistry (IHC) was per-
formed on formalin-fixed paraffin-embedded tissue sections mounted on glass slides. Multiple
slides from each block were generated to reduce sampling error. All IHC steps were carried
out on the Ventana Discovery XT (Ventana Medical Systems) autostainer. Stained slides were
independently reviewed in blinded fashion by a pathologist (L.D.) to assess pattern and
strength of staining. Primary antibodies: phospho-p44/42 MAPK (ERK1/2; Thr202/Tyr204,
Cell Signaling Technology) and Ki67 (clone SP6, LabVision/Thermo Fisher) were used at the
concentration of 1μg/mL and a 1:200 dilution, respectively. Phospho-p44/42 MAPK was
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incubated on slides for 60 minutes at room temperature. Ki67 was incubated on slides for 32
minutes at 37˚C. Ventana OmniMap anti-Rabbit HRP was used as the detection system.
Next-generation sequencing and RT-qPCR
Snap-frozen tumor samples were processed using the AllPrep DNA/RNA isolation kit (Qia-
gen) according to the manufacturer’s protocol to extract both DNA and RNA. Tissue homoge-
nization and lysis was performed with the TissueLyser II (Qiagen). Approximately 30mg of
tissue sample was added to 600μL RLT buffer with a sterilized stainless steel bead (3mm diame-
ter) in a 2mL safe-lock microcentrifuge tube, then quickly transferred to the TissueLyser for 2
minutes at 25 Hz. Lysate was centrifuged at maximum speed for 3 minutes. Supernatant was
transferred to an AllPrep DNA spin column before proceeding to the AllPrep protocol. Clean-
up for RNA samples was done using the RNEasy MinElute kit (Qiagen) according to the man-
ufacturer’s protocol.
Gene expression profiling with RNA-seq was done using a total of 19 tumor samples with
the following genotypes: 9 Ksr1-/- tumors, 7 Ksr1+/- tumors and 3 Ksr1+/+ tumors. Quality con-
trol of samples was done to determine RNA quantity and quality prior to their processing by
RNA-seq. The concentration of RNA samples was determined using NanoDrop 8000 (Thermo
Fisher Scientific) and the integrity of RNA was determined by Fragment Analyzer (Advanced
Analytical Technologies). 0.5μg of total RNA was used as an input material for library prepara-
tion using TruSeq RNA Sample Preparation Kit v2 (Illumina). Size of the libraries was con-
firmed using 4200 TapeStation and High Sensitivity D1K screen tape (Agilent Technologies)
and their concentration was determined by qPCR based method using Library quantification
kit (KAPA). The libraries were multiplexed and then sequenced on HiSeq4000 (Illumina) to
generate ~30 million single end 50 base pair reads.
RNASeq reads were aligned to the human genome version GRCh38 using GSNAP. Expres-
sion counts per gene were obtained by counting the number of reads aligned concordantly
within a pair and uniquely to each gene locus as defined by NCBI and Ensembl gene annota-
tions and RefSeq mRNA sequences. Differential gene expression analysis was performed using
edgeR.
RT-qPCR was performed on RNA extracted from 13 of the 19 tumor samples analyzed for
RNASeq. RNA was reverse transcribed using Superscript III First-Strand Synthesis System for
RT-PCR (Thermo Fisher Scientific) with a starting concentration of 500 ng of RNA and using
Oligo(dT) primers. cDNA from colon, lung and ovary of C57BL/6 mice (Zyagen) was used as
a positive control for KSR2 expression. qPCR was performed using Taqman Universal PCR
Master Mix (Thermo Fisher Scientific) and Taqman primers Mm02745105_m1 (KSR2) and
Mm01171435_gH (EEF2) with FAM-MGB dyes (Thermo Fisher Scientific) with 800ng start-
ing cDNA. qPCR was performed on a Quant Studio 7 Flex (Thermo Fisher Scientific) using
the ΔΔCt method. All samples were run with 3 technical replicates on a single MicroAmp
Optical 96-well Reaction Plate covered with Optical Adhesive Film (Thermo Fisher Scientific).
Statistical analysis
Prism (version 7; GraphPad) was used for analysis and graphing of survival cohorts and qPCR
data. Kaplan-Meier survival statistics were calculated using the log-rank test. P values< 0.05
were considered statistically significant. For qPCR data, comparisons of mean ΔCt for the gene
of interest relative to a reference gene were made for each genotype, with individual tumor
samples treated as biological replicates, using one-way ANOVA with Sidak correction for mul-
tiple comparisons.
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Results
Ksr1-/- mice on the p53 flox/wt background have a slight decrease in all-
cause morbidity
Ksr1-/- mice [11] were bred to the previously described PDAC model with Pdx1-Cre, LSL-
KrasG12D/+ and Trp53flox/flox [22] to generate mice that were homozygous and heterozygous for
KSR1 on the background of p53 homozygous deletion and heterozygous expression of KRAS
G12D. Since the Ksr1 and p53 genes are both on chromosome 11, about 3mB apart, we initially
bred and identified recombinants between these two loci. Haemotoxylin and eosin staining of
the pancreas of Pdx1-Cre;LSL-KrasG12D/+;Trp53flox/flox;Ksr1-/- mice sacrificed at several time
points confirmed the presence of pancreatic ductal adenocarcinoma with tumors identified in
all mice between 3–4 weeks of age. We suspected that the rapid onset and aggressiveness of
tumors in this model might obscure more subtle differences between knockout and wild-type
mice. We therefore generated animals with p53 heterozygosity instead of p53 homozygous
deletion.
We generated Ksr1-/-, Ksr1+/-, and Ksr1+/+ cohorts on the Pdx1-Cre;LSL-KrasG12D/+;
Trp53flox/wt background; unless otherwise stated, we use Ksr1-/-, Ksr1+/-, or Ksr1+/+ as short-
hand to refer to these cohorts which always have the background genotype Pdx1-Cre;LSL-
KrasG12D/+;Trp53flox/wt. Mice were followed weekly and sacrificed after changes in weight and/
or signs of lethargy. Due to ethical concerns, mice were also sacrificed if they developed any
other abnormality that might cause unnecessary suffering, including rectal prolapse. Ages of
mice at sacrifice or death were plotted in a Kaplan-Meier survival curve (Fig 1). The difference
in survival curves for Ksr1+/- and Ksr1+/+ mice was not statistically significant (Fig 1A), and so
they were grouped together to create one control group. When Ksr1-/- mice were compared
with Ksr1+/- and Ksr1+/+ controls (Fig 1B), there was a modest but statistically significant
decrease in all-cause morbidity (median age at sacrifice or death of 191 and 159 days respec-
tively, p = 0.0344 by log-rank comparison). When segregated by gender, it was noted that the 4
of the 7 Ksr1-/- mice sacrificed at 200 days or older mice were female, driving the overall Ksr1-/-
phenotype (S1 Fig). However, despite this trend the sample size was too small to detect a statis-
tically significant difference between male and female mice. A more complete description of
mice in these cohorts is included in S1 Table.
Ksr1-/- mice develop PanIN lesions by 3 months of age
Because Ksr1-/- mice had a modest improvement in overall morbidity, we investigated whether
there might be a delay in the appearance of pre-cancerous pancreatic intraepithelial neoplasms
(PanIN). We sacrificed a cohort of mice from each genotype (3 Ksr1+/+, 3 Ksr1+/-, and 9
Ksr1-/-) at 12 weeks of age and prepared the pancreas for histological analysis. We observed
characteristic noninvasive PanIN lesions, comprising columnar/cuboidal ductal epithelial cells
with variable mucin, in all three groups of mice (Fig 2). There was no obvious difference in
number or severity of lesions between the three groups of mice. Ductal cells in PanIN lesions
for all groups were positive and similar in intensity for pERK staining. In all, there were no
obvious differences in early tumor development in Ksr1-/- mice compared to control animals
in this PDAC model.
Ksr1-/- mice still develop pancreatic ductal adenocarcinoma
While Ksr1-/- mice were generally older before showing signs of morbidity compared to con-
trol animals, all mice eventually succumbed to pancreatic tumors. Histological analysis
revealed that these tumors were ductal adenocarcinomas of similar grade to tumors examined
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from Ksr1+/+ mice, with similar patterns and intensity of pERK and Ki67 staining (Fig 3).
These results demonstrate that KSR1 deficiency does not prevent progression to aggressive
PDAC in a KRAS-driven model with heterozygous loss of p53.
To test the possibility that a different cancer genetic signature emerged in the absence of
KSR1, we compared gene expression by RNA sequencing (RNASeq). RNASeq showed that the
samples were very heterogeneous with no common or distinct molecular signature in Ksr1-/-
tumors compared to tumors from Ksr1+/+ and Ksr1+/- mice (S2A Fig). A subset of the Ksr1-/-
and Ksr1+/- samples that did cluster together (2/9 Ksr1-/- and 2/7 Ksr1+/- tumors) yielded some
Fig 1. Pdx1-Cre;LSL-KrasG12D/+;Trp53flox/wt;Ksr1-/- mice have a modest but statistically significant decrease in all-
cause morbidity. A. Kaplan-Meier curves for Pdx1-Cre;LSL-KrasG12D/+;Trp53flox/wt;Ksr1+/+ and Ksr1+/- mice based on
age at sacrifice or death. 8 Ksr1+/- and 10 Ksr1+/+ mice had to be censored. Median age at sacrifice or death was 152
days for Ksr1+/- mice and 160 days for Ksr1+/+mice; there was no statistically significant difference between the two
groups (p = 0.4683 by log-rank test). B. Kaplan-Meier curves for Pdx1-Cre;LSL-KrasG12D/+;Trp53flox/wt;Ksr1-/-, and
Ksr1+/- combined with Ksr1+/+ mice based on age at sacrifice or death. 3 Ksr1-/- were censored. There was a modest but
statistically significant difference between median age at sacrifice or death for Ksr1-/- mice and the control group (191
and 159 days, p = 0.0344 by log-rank test).
https://doi.org/10.1371/journal.pone.0194998.g001
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statistically significant differences, including downregulation of glucagon and insulin in the
Ksr1-/- samples (S2B Fig). Therefore, expression analysis did not support a distinct genetic sig-
nature in Ksr1-/- compared to Ksr1+/- and Ksr1+/+ tumors. We specifically did not observe an
upregulation in KSR2 message in Ksr1-/- tumors. We further confirmed that there was not a
relative increase in KSR2 with real-time quantitative PCR (RT-qPCR) using the same RNA
samples (S3 Fig).
Ksr1-/- animals are protected from rectal prolapse
We noted that Ksr1+/+ and Ksr1+/- on the PDAC background developed rectal prolapse at a rel-
atively high frequency. 4/22 Ksr1+/+ and 7/17 Ksr1+/- mice developed rectal prolapse and were
sacrificed for that reason. Interestingly, none of the Ksr1-/- mice (0/19) on the PDAC back-
ground developed rectal prolapse. This did not appear to correlate with tumor burden as the
size or extent of tumor was not correlated with the presence or absence of rectal prolapse. As
noted in S1 Table, more female Ksr1+/- mice (6/12) were sacrificed due to rectal prolapse (com-
pared to 1/5 males), while the trend was reversed for Ksr1+/+ mice (1/13 females compared to
3/9 males); however, it should be stressed that our sample size is too small to draw definite
conclusions based on gender. Importantly, exclusion of all animals that developed rectal pro-
lapse from our survival curves did not change the conclusion that Ksr1 deficient animals had a
modest increase in survival compared to the Ksr1 wild-type and heterozygous animals.
Discussion
Given the frequency with which RAS is mutated in cancer, much effort has been focused on
targeting RAS signaling for therapeutic benefit. KSR is a particularly attractive target because it
is known to positively regulate MAPK signaling in the context of constitutively active RAS [1–
3, 13–16, 23]. It also does not appear to be essential in normal cells, and so its inhibition might
be expected to synergize with compounds that target other components of the MAP kinase sig-
naling pathway without increasing toxicity. Indeed, one group has already reported a KSR-spe-
cific inhibitor that can synergize with the MEK inhibitor trametinib to decrease viability of
RAS mutant cell lines [24]. Previously, we showed that KSR1 deficiency attenuated both the
number and the growth of tumors that developed using the MMTV breast cancer model [11].
Another group used antisense oligonucleotides to demonstrate that KSR1 knockdown could
Fig 2. Pdx1-Cre;LSL-KrasG12D/+;Trp53flox/wt;Ksr1-/- mice develop PanIN lesions at similar rates and severity to Ksr1+/-
and Ksr1+/+ mice. H&E staining of pancreatic tissues from Pdx1-Cre;LSL-KrasG12D/+;Trp53flox/wt;Ksr1+/+, Ksr1+/ -, and
Ksr1-/- mice sacrificed at 3 months of age highlights PanIN lesions surrounded by normal tissue (bar = 40μm).
https://doi.org/10.1371/journal.pone.0194998.g002
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Fig 3. Pdx1-Cre;LSL-KrasG12D/+;Trp53flox/wt;Ksr1-/- mice develop pancreatic tumors. H&E (top), pERK (middle) and Ki67 (bottom) staining of tumors
harvested from Pdx1-Cre;LSL-KrasG12D/+;Trp53flox/wt;Ksr1+/+, Ksr1+/-, and Ksr1-/- mice (bar = 100μm). Panels to the right show magnification of indicated
region (bar = 40μm). Tumors have moderately differentiated ductal morphology that stains strongly for pERK, accompanied by stromal desmoplasia. Ki67
stains some ductal and surrounding cells.
https://doi.org/10.1371/journal.pone.0194998.g003
Role of KSR1 in a mouse model of KRAS driven pancreatic cancer
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reduce growth of KRAS-dependent human pancreatic carcinoma xenografts in nude mice
[16].
We therefore wanted to determine the effect of KSR1 deletion in a well-characterized
mouse model of KRAS-driven pancreatic cancer. We found that the loss of KSR1 resulted in a
modest, but statistically significant decrease in morbidity; however, all mice eventually suc-
cumbed to pancreatic tumors. This is somewhat surprising in light of previous work using
antisense oligonucleotides [16], but our study is the first to test the role of KSR1 using this
genetically engineered mouse model of PDAC. It is possible that the loss of KSR1 in the stro-
mal or immune compartment could have compensated for the loss of KSR1 in tumor cells, or
that KSR1 deletion caused developmental changes which circumvented KSR1 dependence for
tumors in this particular model. It is also possible that this PDAC model is so robust that it
masks a role for KSR1 which might be seen in other contexts of aberrant RAS signaling. Of
note, our study incorporated KSR1 depletion in all tissues, while Xing et al. [16] used antisense
oligonucleotides. Since the efficacy of KSR1 knockdown with antisense oligonucleotides corre-
lates with cellular uptake and not with plasma levels [25], the effect of antisense oligonucleo-
tides may have been greater in certain cells, including tumor cells, compared with other
tissues, such as the immune compartment. Future studies using a KSR1 conditional knockout
could help resolve some of these discrepancies. Notably, there may be important clinical dis-
tinctions between KSR1 knockdown, altering its conformation, and complete KSR1 deficiency,
and so our results do not necessarily contradict efforts to target KSR1 for therapeutic benefit.
We can conclude that in this specific mouse model of pancreatic cancer, KSR1 signaling
was not required for tumorigenesis. However, this does not rule out a role for KSR in other set-
tings, especially in light of previous reports suggesting it is a positive regulator of RAS signaling
[1–3, 11, 23, 26, 27]. In a study of human breast cancer where RAS mutations are rare, high
KSR1 levels were shown to correlate with overall survival, and mechanistic studies suggested
that this is due to KSR1 stabilization of BRCA1 [28]. KSR may therefore have functions outside
of MAPK modulation that could impact cell growth and proliferation.
Of note, in our model we used a p53 deleted allele, while most genetically engineered
PDAC mouse models use the p53 R172H hypomorph [29–33]. A previous study directly com-
paring heterozygous deletion of p53 to heterozygous expression of p53 R172H in the same
PDAC model showed no difference in tumor latency or survival. However, 13/20 of hypo-
morphic p53 mutant mice had liver metastases compared to 0/20 of mice with the heterozy-
gous p53 deletion [34]. Similarly, we rarely observed liver metastases in our mice, and it is
therefore possible that using the deleted p53 allele might have masked a biological role of
KSR1 in promoting p53-driven metastases.
One hypothesis is that KSR2 could be compensating for the absence of KSR1. We did not,
however, detect KSR2 expression in the pancreas nor did we see it upregulated in the RNASeq
analysis performed on Ksr1-/- mouse tumors. We further confirmed with RT-qPCR that rela-
tive KSR2 expression did not increase in Ksr1-/- compared to Ksr1+/+ tumor samples, and so a
compensatory role for KSR2 is less likely. With RNASeq, we were also unable to detect a differ-
ence in genetic signature based on KSR1 genotype. While this could be consistent with the
absence of a strong phenotypical difference between Ksr1-/- and Ksr1+/+ mice, it may also
reflect the heterogeneity of the tumors analyzed. All these caveats are important to keep in
mind for future studies of KSR.
One unexpected finding that arose during the course of this study was a high frequency of
rectal prolapse that occurred in the Ksr1+/+ and Ksr1+/- cohorts (4/22 and 7/17 respectively).
Because of ethical concerns, we were forced to sacrifice these mice at the time we noticed the
prolapse. Prolapse did not correlate with the presence of gross tumor at sacrifice, nor with the
size or extent of tumor. Importantly, removal of all animals with prolapse did not have any
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significant effect on the overall survival statistics. We do not know why Ksr1-/- mice were pro-
tected from the development of rectal prolapse, nor why its incidence has not been docu-
mented in other reports. One previous study did mention rectal prolapse in passing as a
reason for censorship in survival analysis of Pdx1-Cre;LSL-KrasG12D/+;Trp53LSL-R172H/wt mice
[35]. It is possible that in our cohort, PDX1-Cre is expressed in cells in the intestine or that the
absence of KSR1 in immune cells is causing a defect in the intestinal barrier through perhaps a
change in the microbiome. Preliminary histology from a mouse with prolapse showed a mild
to moderate enteritis in the small bowel with an inflammatory infiltrate and apoptotic cells
throughout the intestinal crypts, as well as a mild increased inflammatory infiltrate in the
colon. Our results suggest a protective effect in Ksr1-/- mice that would be interesting to inves-
tigate in future studies.
Overall, the trend toward decreased morbidity with Ksr1-/- mice that we observed was mod-
est and all mice eventually developed invasive ductal adenocarcinoma. Even though our study
does not point to an essential function for KSR1 in KRAS-driven pancreatic cancer with het-
erozygous loss of p53, we cannot rule out a supporting role for KSR1, or a function in other
contexts, and further work will be needed to dissect the complexities of KSR signaling.
Supporting information
S1 Table. Characteristics of mice in survival cohort. Note that 7/17 Ksr1+/- and 4/22 Ksr1+/+
mice had to be sacrificed due to the development of rectal prolapse.
(DOCX)
S1 Fig. Kaplan-Meier curves for Pdx1-Cre;LSL-KrasG12D/+;Trp53flox/wt;Ksr1-/- mice versus
Pdx1-Cre;LSL-KrasG12D/+;Trp53flox/wt;Ksr1+/- and Ksr1+/+ mice according to gender. While
there was a trend toward Ksr1-/- females sacrificed at an older age, given the sample size the dif-
ference is not statistically significant (p = 0.0683). There were also no other statistically signifi-
cant differences between the different gender cohorts.
(TIF)
S2 Fig. mRNA expression in tumors harvested from Ksr1 cohorts do not cluster by geno-
type. A. Unsupervised clustering of mRNA expression across the entire transcriptome. Ksr1
genotypes are indicated as KO (knockout), HET (heterozygous) and WT (wild-type). B. Two
Ksr1-/- and two Ksr1+/- tumor samples were selected that each clustered based on whole tran-
scriptome analysis. Depicted here are the top 100 candidates differentially expressed between
the two genotypes. Four genes downregulated in Ksr1-/- samples are listed with their respective
p values (a complete list is included in S1 File).
(TIF)
S3 Fig. Relative KSR2 expression does not increase in Ksr1-/- compared to Ksr1+/+ tumor
samples. RT-qPCR was performed on the same tumor RNA samples used for RNASeq. ΔCT
values were calculated by subtracting KSR2 CT values from CT values for the reference gene,
EEF2; accordingly, higher ΔCT values correspond to lower KSR2 expression. Each tumor sam-
ple is plotted as an individual point with error bars representing the standard deviation of the
mean ΔCT for three technical replicates. Mean ΔCT values were not significantly different
between 3 Ksr1+/+, 5 Ksr1+/-, and 5 Ksr1-/- tumor samples (difference in ΔCT between Ksr1+/+
and Ksr1-/-: -0.11, 95% confidence interval [CI] -2.92 to 2.71; between Ksr1+/- and Ksr1-/-: -0.52,
95% CI -2.96 to 1.92; between Ksr1+/+ and Ksr1+/-: 0.41, 95% CI -2.40 to 3.23). RNA extracted
from mouse colon, lung and ovary was used for positive controls.
(TIF)
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